CN112867496A - 用于治疗神经退行性疾病的基于car-treg的疗法 - Google Patents

用于治疗神经退行性疾病的基于car-treg的疗法 Download PDF

Info

Publication number
CN112867496A
CN112867496A CN201980035934.XA CN201980035934A CN112867496A CN 112867496 A CN112867496 A CN 112867496A CN 201980035934 A CN201980035934 A CN 201980035934A CN 112867496 A CN112867496 A CN 112867496A
Authority
CN
China
Prior art keywords
protein
disease
marker
glial
treg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980035934.XA
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·G·艾什顿-里卡德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aztherapies Inc
Original Assignee
Smith Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Treatment Co filed Critical Smith Treatment Co
Publication of CN112867496A publication Critical patent/CN112867496A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980035934.XA 2018-03-27 2019-03-21 用于治疗神经退行性疾病的基于car-treg的疗法 Pending CN112867496A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648684P 2018-03-27 2018-03-27
US62/648,684 2018-03-27
PCT/US2019/023395 WO2019190879A1 (en) 2018-03-27 2019-03-21 Car-treg-based therapies for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CN112867496A true CN112867496A (zh) 2021-05-28

Family

ID=68060734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980035934.XA Pending CN112867496A (zh) 2018-03-27 2019-03-21 用于治疗神经退行性疾病的基于car-treg的疗法

Country Status (8)

Country Link
US (2) US12173030B2 (enExample)
EP (1) EP3773629A4 (enExample)
JP (3) JP2021531280A (enExample)
KR (2) KR102892999B1 (enExample)
CN (1) CN112867496A (enExample)
AU (1) AU2019242381B2 (enExample)
CA (1) CA3095298A1 (enExample)
WO (1) WO2019190879A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102892999B1 (ko) 2018-03-27 2025-11-28 아즈테라피즈 인코포레이티드 신경변성 질환을 치료하기 위한 CAR-Treg-기반 요법
CN116134144A (zh) 2020-04-23 2023-05-16 Az治疗股份有限公司 细胞的hla-i类mhc消融
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
CN117957246A (zh) * 2021-09-03 2024-04-30 桑格摩生物治疗股份有限公司 Mog结合蛋白和其用途
WO2023047098A2 (en) * 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-p75ntr chimeric antigen receptor
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
US20140024809A1 (en) * 2011-02-11 2014-01-23 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
US20160184367A1 (en) * 2014-12-30 2016-06-30 The Brigham And Women's Hospital, Inc. Methods to improve cell therapy
WO2017100428A1 (en) * 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
US20210023137A1 (en) * 2018-03-27 2021-01-28 Smith Therapeutics Inc. Car-treg-based therapies for treating neurodegenerative diseases
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046828A2 (en) 2006-07-07 2009-04-15 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
KR20140071277A (ko) * 2011-05-19 2014-06-11 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
MX393951B (es) * 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
CN111357090B (zh) * 2017-11-11 2024-01-05 微材料有限责任公司 用于高压处理腔室的气体输送系统

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
US20140024809A1 (en) * 2011-02-11 2014-01-23 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
US20160184367A1 (en) * 2014-12-30 2016-06-30 The Brigham And Women's Hospital, Inc. Methods to improve cell therapy
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2017100428A1 (en) * 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
US20210023137A1 (en) * 2018-03-27 2021-01-28 Smith Therapeutics Inc. Car-treg-based therapies for treating neurodegenerative diseases
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOTAHAREH ARJOMANDNEJAD等: "CAR-T Regulatory （CAR-Treg） Cells：Engineering and Application", BIOMEDICINES, vol. 10, no. 2, 26 January 2022 (2022-01-26), pages 1 - 21 *
王鹏程等: "嵌合抗原受体T细胞免疫治疗在自身免疫病的研究进展", 肾脏病与透析肾移植杂志, vol. 28, no. 6, 28 December 2019 (2019-12-28), pages 550 - 555 *
詹启敏等: "《精准医学总论》", 31 December 2017, 上海交通大学出版社, pages: 105 - 106 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Also Published As

Publication number Publication date
US20210023137A1 (en) 2021-01-28
JP2025123315A (ja) 2025-08-22
WO2019190879A1 (en) 2019-10-03
CA3095298A1 (en) 2019-10-03
EP3773629A1 (en) 2021-02-17
AU2019242381A1 (en) 2020-11-19
KR102892999B1 (ko) 2025-11-28
US20250129158A1 (en) 2025-04-24
JP2024086870A (ja) 2024-06-28
KR20250174989A (ko) 2025-12-15
JP7697096B2 (ja) 2025-06-23
KR20210135921A (ko) 2021-11-16
US12173030B2 (en) 2024-12-24
AU2019242381B2 (en) 2025-04-24
JP2021531280A (ja) 2021-11-18
EP3773629A4 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
JP7697096B2 (ja) 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2022046822A (ja) 中枢神経系の疾患および障害を処置するための組成物および方法
Kim et al. Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma
JP6416131B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
Manjunatha et al. Multiple sclerosis: therapeutic strategies on the horizon
JP2011513493A (ja) 血液脳関門透過性の調節方法
SA515360253B1 (ar) أجسام مضادة مُميزة لألفا سينوكلين
JP2014516510A (ja) 抗上皮成長因子受容体変異体ｉｉｉキメラ抗原受容体及び癌の治療のためのその使用
TWI717848B (zh) 抗體於治療神經退化性疾病的用途
Shen et al. Systemic delivery of mPEG‐masked trispecific T‐cell nanoengagers in synergy with STING agonists overcomes immunotherapy resistance in TNBC and generates a vaccination effect
JP2008537736A5 (enExample)
JP2020528455A (ja) ドナー改変細胞の選択のための調節可能スイッチ
JP2023531378A (ja) 神経変性疾患を治療するためのＣＡＲ－Ｔｒｅｇ系療法
KR20070007291A (ko) 면역 반응을 유도하거나 조절하는 방법
Gris et al. Gene expression profiling in anti-CD11d mAb-treated spinal cord-injured rats
CN115850509A (zh) 抗原结合蛋白及其用途
US20190328781A1 (en) Manufacturing methods for cell-based therapeutic compositions
Coles Alastair Compston, Alasdair Coles
JP2024546828A (ja) 標的異常細胞を治療する新規な方法とそこで使用される細胞傷害性細胞
JP2003531859A (ja) ミコバクテリアを用いた中枢神経症状の治療
WO2025250591A1 (en) Abc and gate car-t cell therapy for autoimmune disease
WANG et al. Temporal variability of neurography
NZ733855B2 (en) Universal killer t-cell

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210601

Address after: Massachusetts, USA

Applicant after: AZTherapies, Inc.

Address before: Massachusetts, USA

Applicant before: Smith treatment Co.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination